Effects of metformin on autoimmune immunoglobins and interferon‐γ in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial. (1st January 2022)

• Record Type: Journal Article
• Authors: Rahmatpour Rokni, G.; Shiran, M.; Abounoori, M.; Houshmand, G.; Babakhanian, M.; Godazandeh, G.; Bayat, S.; Pazyar, N.; Abedi, M.; Khorshidi, F.; Yari, F.; Ghafouri, Z.; Patil, A.; Goldust, M.; Mirmohammadi Langari, L.
• Is Part Of: Clinical and experimental dermatology. Volume 47:Number 1(2022)
• Page Start: 110
• Page End: 113
• Publication Date: 2022-01-01
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.14832
• Languages: English
• ISSNs: 0307-6938

Abstract

Abstract: The management of pemphigus vulgaris (PV) is challenging. This study aimed to evaluate the immunomodulating effects of metformin on PV. The study was conducted in two phases: in the first phase, patients received routine first‐line treatment (prednisolone plus azathioprine) for 2 months, then in the second phase, metformin was added to this regimen for another 2 months. After addition of metformin to the first‐line medications, significant reductions were seen in serum IgG1 (reduced from 534.92 ± 134.83 mg/dL to 481.58 ± 130.46 mg/dL, P < 0.001), IgG4 (51.83 ± 27.26 mg/dL to 44.50 ± 26.05 mg/dL, P < 0.001) and interferon‐γ (277.99 ± 108.71 pg/mL to 45.05 ± 17.080 pg/mL, P = 0.03) concentrations. The suppressant effect of metformin was greatest on IgG4 (coefficient of variation 1.28), the dominant subclass of IgG involved in PV. Metformin could have immunomodulating effects on PV with controlling effects on steroid complications.